AveloxThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10

473 records returned

The Newer FluoroquinolonesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article reviews fluoroquinolone pharmacology, pharmacodynamic principles, and fluoroquinolone resistance mechanisms, highlighting recent trends in the epidemiology of fluoroquinolone resistance among gram-negative organisms and Streptococcus pneumonia. Important fluoroquinolone safety concerns are discussed, along with indications for the most commonly used fluoroquinolones—ciprofloxacin, levofloxacin, and moxifloxacin. (Source: Infectious Diseases Clinics of North America)
Source: Infectious Diseases Clinics of North America - November 12, 2009 Category: Infectious Diseases Authors: Maureen K. Bolon Source Type: journals

In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in TaiwanEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Our findings point to a potentially useful role for nemonoxacin in the treatment of infections caused by MSSA, ciprofloxacin-susceptible MRSA and S. pneumoniae with various resistance phenotypes. (Source: Journal of Antimicrobial Chemotherapy)
Source: Journal of Antimicrobial Chemotherapy - November 10, 2009 Category: Microbiology Authors: Chen, Y.-H., Liu, C.-Y., Lu, J.-J., King, C.-H. R., Hsueh, P.-R. Tags: Original research Source Type: journals

Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Sunitinib has a dose-dependent effect on QT interval. The increased risk of ventricular arrhythmias must be weighed against the therapeutic benefit sunitinib provides to patients with advanced cancer. (Clin Cancer Res 2009;15(22):7045-52). PMID: 19903787 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - November 10, 2009 Category: Cancer & Oncology Authors: Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van Vugt A, Toh M, Baum C, Rosen L Tags: Clin Cancer Res Source Type: journals

Newer Fluoroquinolones May Improve Outcome in Extensively Drug-Resistant TBEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Later-generation fluoroquinolones, such as levofloxacin, moxifloxacin, and sparfloxacin, show efficacy in the treatment of extensively drug-resistant tuberculosis (TB).Later-generation fluoroquinolones, such as levofloxacin, moxifloxacin, and sparfloxacin, show efficacy in the treatment of extensively drug-resistant tuberculosis (TB). Medscape Medical News (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - November 6, 2009 Category: Respiratory Medicine Tags: Infectious Diseases Source Type: info

Moxifloxacin effective for PPM eradication in COPD patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Treatment with the antibiotic moxifloxacin is effective at eradicating potentially pathogenic microorganisms in the airways of patients with chronic obstructive pulmonary disease, but does not prevent recolonization, research shows. (Source: MedWire News - Respiratory)
Source: MedWire News - Respiratory - November 5, 2009 Category: Respiratory Medicine Source Type: news

A severely symptomatic case of anaerobic chronic bacterial prostatitis successfully resolved with moxifloxacin therapy.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
It has been demonstrated that patients showing symptoms of chronic bacterial prostatitis but culture-negative prostate-specific specimens can benefit from administration of antibacterial agents. This suggests that organisms that are not isolated in the routine practice may be responsible for prostate infection in an undefined fraction of subjects. Anaerobic bacteria have been proposed to play a pathogenic role in CBP, on the basis of studies describing clinical remission after eradication of pathogens like Peptostreptococcus spp. or Bacterioides spp. from prostatic secretions of symptomatic patients, or the significant...
Source: Anaerobe - October 30, 2009 Category: Microbiology Authors: Magri V, Restelli A, Marras E, Perletti G Tags: Anaerobe Source Type: journals

Moxifloxacin-induced changes in T-wave morphologyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we evaluate changes in T-wave morphology (MCS) and QTc induced by moxifloxacin, an industry benchmark for subtle repolarization effects. (Source: Journal of Electrocardiology)
Source: Journal of Electrocardiology - October 24, 2009 Category: Cardiology Authors: C. Graff, J. Matz, M.P. Andersen, J.K. Kanters, E. Toft, J. Xue, J.J. Struijk Tags: Poster Session 1 and 2 Source Type: journals

Manual and automatic measurements of moxifloxacin-induced QT prolongationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Accurate measurement of QT intervals is of pivotal importance in cardiac safety trials. Thorough QT studies must be designed to detect an 8- to 12-millisecond ΔΔQTc prolongation in a positive control group treated with moxifloxacin. QT measurements are typically performed manually to maximize measurement accuracy. Automatic QT measurements are more cost-effective, but the ability of commercial algorithms to detect moxifloxacin-induced QTc prolongation should be investigated. (Source: Journal of Electrocardiology)
Source: Journal of Electrocardiology - October 24, 2009 Category: Cardiology Authors: M.P. Andersen, J. Matz, C. Graff, J.K. Kanters, E. Toft, J.J. Struijk Tags: Poster Session 1 and 2 Source Type: journals

Synthesis and evaluation of (99m)Tc-moxifloxacin, a potential infection specific imaging agent.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To synthesize and evaluate a (99m)Tc labeled fluroquinolone, moxifloxacin as a potential bacteria specific infection imaging agent. A radiolabeling formulation including moxifloxacin, [Moxicip(TM) injection, Cipla] (4mg), sodium pertechnetate and stannous chloride (5mug) gave the best radiolabeling efficiency and moderately stable labeled (99m)Tc moxifloxacin. Quality control analysis was performed by ITLC. Rats and rabbit with infectious intramuscular lesions induced in either thigh with E. Colli were used for studying biodistribution and scintigraphic imaging of the labeled product. Imaging of an infected thigh of a ...
Source: Applied Radiation and Isotopes - October 24, 2009 Category: Radiology Authors: Chattopadhyay S, Saha Das S, Chandra S, De K, Mishra M, Ranjan Sarkar B, Sinha S, Ganguly S Tags: Appl Radiat Isot Source Type: journals

AVELOX (Moxifloxacin Hydrochloride) Tablet, Film Coated [Physicians Total Care, Inc.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Oct 23, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - October 23, 2009 Category: Drugs & Pharmacology Source Type: organizations

Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
& E Van Aken (Source: Eye)
Source: Eye - October 22, 2009 Category: Opthalmology Authors: M Wefers Bettink-RemeijerK BrouwersL van LangenhoveP W T De WaardT O MissottenJ P Martinez CirianoE Van Aken Source Type: journals

Acute Granulomatous Acanthamoeba Encephalitis in an Immunocompetent PatientEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions This case report demonstrates successful treatment of usually lethal GAE in an immunocompetent patient with high dose meropenem, linezolid, moxifloxacin and fluconazole followed by a partially adapted antimicrobial combination therapy. Content Type Journal ArticleCategory Practical PearlDOI 10.1007/s12028-009-9291-zAuthors Peter Lackner, Innsbruck Medical University Department of Neurology 6020 Innsbruck, Anichstrasse 35 Austria EuropeRonny Beer, Innsbruck Medical University Department of Neurology 6020 Innsbruck, Anichstrasse 35 Austria EuropeGregor Broessner, Innsbruck Medical University ...
Source: Neurocritical Care - October 22, 2009 Category: Neurology Tags: Neurocritical Care Source Type: journals

Abuse of Antibiotic Prophylaxis in Third Molar SurgeriesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
I read with interest the article by Limeres et al, “Patients' perception of recovery after third molar surgery following postoperative treatment with moxifloxacin versus amoxicillin and clavulanic acid: A randomized, double-blind, controlled study,” describing the effect of antibiotic prophylaxis on patients' quality of life after third molar surgeries. Although the authors arrived at some valuable conclusions, the study also has some major shortcomings. (Source: Journal of Oral and Maxillofacial Surgery)
Source: Journal of Oral and Maxillofacial Surgery - October 20, 2009 Category: ENT & OMF Authors: Tomasz Kaczmarzyk Tags: Letters to the Editor Source Type: journals

AVELOX (Moxifloxacin Hydrochloride) Tablet, Film Coated [Physicians Total Care, Inc.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Oct 20, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - October 20, 2009 Category: Drugs & Pharmacology Source Type: organizations

Levofloxacin trumps moxifloxacin for CAPEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 19, 2009 Category: Health Management Tags: Research article Source Type: journals

Antituberculars/moxifloxacin: Atopic dermatitis (first report with moxifloxacin) in an elderly patient: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 19, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Absence of Effect of Telbivudine on Cardiac Repolarization: Results of a Thorough QT/QTc Study in Healthy Participants.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study therefore met the criteria for a negative thorough QT study. Telbivudine had no adverse effect on cardiac repolarization in healthy participants, even at supratherapeutic exposure, suggesting a broad safety margin. PMID: 19833860 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Pharmacology)
Source: The Journal of Clinical Pharmacology - October 14, 2009 Category: Drugs & Pharmacology Authors: Poordad F, Zeldin G, Harris SI, Ke J, Xu L, Mayers D, Zhou XJ Tags: J Clin Pharmacol Source Type: journals

Lack of Electrocardiographic Effect of Dexlansoprazole MR, a Novel Modified-Release Formulation of the Proton Pump Inhibitor Dexlansoprazole, in Healthy Participants.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The effect of the proton pump inhibitor dexlansoprazole, an enantiomer of lansoprazole, on QT intervals was assessed after oral administration of a modifiedrelease formulation of dexlansoprazole (dexlansoprazole MR). In this randomized, positivecomparator, placebocontrolled, 4period crossover study, 40 healthy participants received single doses of dexlansoprazole MR 90 mg, dexlansoprazole MR 300 mg, moxifloxacin 400 mg, and placebo separated by 5day washout intervals. Twentyfourhour electrocardiograms were obtained at baseline and during each dosing period. The number and percentage of participants experiencing an incr...
Source: The Journal of Clinical Pharmacology - October 12, 2009 Category: Drugs & Pharmacology Authors: Vakily M, Wu J, Atkinson SN Tags: J Clin Pharmacol Source Type: journals

Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infectionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The results show that moxifloxacin penetrates well into gallbladder tissue and is therefore a therapeutic option for biliary tract infection. The highest concentrations in serum and gallbladder tissue were measured shortly after the end of a 1 h infusion. As perioperative prophylaxis, moxifloxacin should therefore be administered 30–60 min before the first surgical incision. (Source: Journal of Antimicrobial Chemotherapy)
Source: Journal of Antimicrobial Chemotherapy - October 12, 2009 Category: Microbiology Authors: Ober, M. C., Hoppe-Tichy, T., Koninger, J., Schunter, O., Sonntag, H.-G., Weigand, M. A., Encke, J., Gutt, C., Swoboda, S. Tags: Original research Source Type: journals

Flucloxacillin, still the empirical choice for putative Staphylococcus aureus infections in intensive care units in the NetherlandsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The empirical choice of flucloxacillin in the case of putative S. aureus infections in patients admitted to ICUs in the Netherlands is still justified. (Source: Journal of Antimicrobial Chemotherapy)
Source: Journal of Antimicrobial Chemotherapy - October 12, 2009 Category: Microbiology Authors: Rijnders, M. I. A., Deurenberg, R. H., Boumans, M. L. L., Hoogkamp-Korstanje, J. A. A., Beisser, P. S., Stobberingh, E. E., on behalf of the Antibiotic Resistance Surveillance Group Tags: Original research Source Type: journals

Moxifloxacin: QT interval prolongation and torsade de pointes in an elderly patient: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 12, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Metronidazole/moxifloxacin: Orthostatic hypotension, nausea, vomiting and recurrent C. difficile infection, treated with nitazoxanide and probiotics: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 12, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This multicentre, double-blind study was undertaken to demonstrate non-inferiority of once-daily oral moxifloxacin compared with combination therapy in the management of acute, uncomplicated pelvic inflammatory disease (PID). Women aged ≥18 years with PID were randomized to receive moxifloxacin (400 mg once daily) for 14 days or comparator treatment (doxycycline [100 mg twice daily] plus metronidazole [400 mg three times daily] for 14 days, plus one single 500-mg ciprofloxacin dose). Of the 434 valid per protocol (PP) patients, the overall clinical success rates at 2–14 days post-therapy were 96.6% (moxifloxacin) ...
Source: International Journal of STD and AIDS - October 8, 2009 Category: Global & Universal Authors: Heystek, M, Ross, J D C, for the PID Study Group Tags: Original research articles Source Type: journals

Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: DARE Area: Evidence > Disease Focused Reviews CRD Summary: This review assessed whether improved clinical and mortality outcomes are achieved for outpatient community acquired pneumonia treated with antibacterials with coverage against atypical organisms. The authors concluded that there was no evidence of superiority for any drug comparison. Given some methodological uncertainties identified in the review process, the extent to which this conclusion was reliable was unclear. [The included studies assessed the following oral therapies at differing doses: fluoroquinolones (moxifloxacin, sparfloxacin, levofloxacin...
Source: NeLM - Infectious Diseases - October 8, 2009 Category: Infectious Diseases Source Type: organizations

Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To characterize the extent and diversity of moxifloxacin resistance among Clostridium difficile isolates recovered during a predominantly Anaerobe Reference Unit (ARU) ribotype 027-associated nosocomial outbreak of antibiotic associated diarrhea we measured the susceptibility of 34 field isolates and 6 laboratory strains of C. difficile to moxifloxacin. We ribotyped the isolates as well as assaying them by PCR for the metabolic gene, gdh, and the virulence genes, tcdA, tcdB, tcdC, cdtA and cdtB. All the laboratory isolates, including the historical ARU 027 isolate Cd196, were susceptible to moxifloxacin (</= 2mug/mL...
Source: Anaerobe - October 6, 2009 Category: Microbiology Authors: Carman RJ, Genheimer CW, Rafii F, Park M, Hiltonsmith MF, Lyerly DM Tags: Anaerobe Source Type: journals

Effects of Subinhibitory Concentrations of Antibiotics on Colonization Factor Expression by Moxifloxacin-Susceptible and Moxifloxacin-Resistant Clostridium difficile Strains.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective of this study was to analyze expression of these genes in the same conditions in four NAP1/027 strains, one moxifloxacin-susceptible and three moxifloxacin-resistant strains. Two in vitro selected moxifloxacin-resistant mutants were also analyzed. Moxifloxacin resistance was associated to the Thr82-->Ile substitution in GyrA in all moxifloxacin-resistant strains but one. The expression of cwp84 and slpA was strongly increased after culture with ampicillin or clindamycin in NAP1/027 strains. Interestingly, after culture with fluoroquinolones, the expression of cwp84 and slpA was only increased in four moxif...
Source: Antimicrobial Agents and Chemotherapy - October 4, 2009 Category: Microbiology Authors: Denève C, Bouttier S, Dupuy B, Barbut F, Collignon A, Janoir C Tags: Antimicrob Agents Chemother Source Type: journals

Bacterial strain-to-strain variation in the pharmacodynamic index magnitude: a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Antibiotic pharmacodynamic modelling allows variations in pathogen susceptibility and human pharmacokinetics to be accounted for when considering antibiotic doses, potential bacterial pathogen targets for therapy, and clinical susceptibility breakpoints. Variation in the pharmacodynamic index (AUC24/MIC, Cmax/MIC, T>MIC) is not usually considered. In an in vitro pharmacokinetic model of infection using a dose ranging design, we established the relationship between AUC24/MIC and antibacterial effect for moxifloxacin against 10 strains of S. aureus. The distributions of AUC24/MIC targets for a 24h static, 1-log, 2-log...
Source: Antimicrobial Agents and Chemotherapy - October 4, 2009 Category: Microbiology Authors: Macgowan AP, Reynolds R, Noel AR, Bowker KE Tags: Antimicrob Agents Chemother Source Type: journals

Anti-inflammatory effects of antibacterials on human bronchial epithelial cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background: Human Bronchial epithelial cells (hu-BEC) have been claimed to play a significant role in the pathogenesis of chronic inflammatory airway diseases like COPD. In this context IL-8 and GM-CSF have been shown to be key cytokines. Some antibiotics which are routinely used to treat lower respiratory tract infections have been shown to exert additional immunomodulatory or anti-inflammatory effects. We investigated whether these effects can also be detected in hu-BEC. Methods: Hu-BEC obtained from patients undergoing lung resections were transferred to air-liquid-interface (ALI) culture. These cultures were incubated ...
Source: BioMed Central - September 28, 2009 Category: Journals (General) Authors: Gregor ZimmermannClaus NeurohrHeidrun Villena-HermozaRudolf HatzJuergen Behr Source Type: journals

One-day application of topical moxifloxacin 0.5% to select for fluoroquinolone-resistant coagulase-negative StaphylococcusEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Purpose: To compare selection for fluoroquinolone-resistant bacteria between 1-day and 3-day application of topical moxifloxacin 0.5%.Setting: Department of Ophthalmology, Stanford University, Stanford, California, USA.Methods: After investigative review board approval, patients scheduled for ocular surgery were randomized to receive topical moxifloxacin 0.5% drops 4 times a day for 1 day or 3 days preoperatively. Conjunctival cultures were obtained at baseline and after antibiotic application. Bacteria were identified and tested for resistance to a battery of antibiotic agents using the Kirby-Bauer disk-diffusion method. ...
Source: Journal of Cataract and Refractive Surgery - September 24, 2009 Category: Opthalmology Authors: Lingmin He, Christopher N. Ta, Herminia Miño de Kaspar Tags: Articles Source Type: journals

Should moxifloxacin be substituted for isoniazid as a first-line antituberculosis drug?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19762595 [PubMed - in process] (Source: American Journal of Respiratory and Critical Care Medicine)
Source: American Journal of Respiratory and Critical Care Medicine - September 19, 2009 Category: Respiratory Medicine Authors: Mohapatra PR Tags: Am J Respir Crit Care Med Source Type: journals

Efficacy and Safety of Sequential Intravenous/Oral Moxifloxacin vs Intravenous/Oral Amoxicillin/Clavulanate for Complicated Skin and Skin Structure InfectionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Treatment with sequential iv/po moxifloxacin monotherapy once daily is clinically comparable to that with iv/po amoxicillin/clavulanate three times daily in the management of cSSSIs. Moxifloxacin’s simple dose regimen offers an advantage over amoxicillin/clavulanate and represents a valuable addition to current antibiotic regimens used in the treatment of cSSSIs. Content Type Journal ArticleCategory Clinical and Epidemiological StudyDOI 10.1007/s15010-009-8468-xAuthors R. Vick-Fragoso, Hospital General “Dr Manuel Gea González” Infectious Disease Dept. Calzada de Tlalpan Tlalpan, Mex...
Source: Infection - September 18, 2009 Category: Infectious Diseases Tags: Infection Source Type: journals

In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001–2006Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study found that moxifloxacin and tigecycline exhibited good in vitro activity against bacterial isolates causing IAIs. Content Type Journal ArticleCategory ArticleDOI 10.1007/s10096-009-0801-xAuthors C.-Y. Liu, National Taiwan University College of Medicine Department of Internal Medicine, National Taiwan University Hospital Taipei TaiwanC.-L. Lu, National Taiwan University College of Medicine Department of Internal Medicine, National Taiwan University Hospital Taipei TaiwanY.-T. Huang, National Taiwan University College of Medicine Department of Laboratory Medicine, National Taiwan University Hospital Taipei T...
Source: European Journal of Clinical Microbiology & Infectious Diseases - September 17, 2009 Category: Microbiology Tags: European Journal of Clinical Microbiology & Infectious Diseases Source Type: journals

[Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? : In vitro safety profile for intraocular application.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Vigamox(R) did not show significant toxicity on primary RPEs, TMCs, LECs, CECs, or human corneal endothelium at concentrations up to 150 microg/ml. The MIC90 of moxifloxacin for pathogens commonly encountered in endophthalmitis is known to be in the range of 0.25-2.5 microg/ml. Therefore, intracameral use of Vigamox(R) at concentrations up to 150 microg/ml may be safe and effective for preventing endophthalmitis after intraocular surgery. PMID: 19756636 [PubMed - as supplied by publisher] (Source: Der Ophthalmologe)
Source: Der Ophthalmologe - September 16, 2009 Category: Opthalmology Authors: Kernt M, Hirneiss C, Neubauer AS, Liegl RG, Eibl KH, Wolf A, de Kaspar H, Ulbig MW, Kampik A Tags: Ophthalmologe Source Type: journals

Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Stenotrophomonas maltophilia is an emerging nosocomial bacterial pathogen which is currently isolated with increasing frequency from the airways of cystic fibrosis (CF) patients. We evaluated the effect of subinhibitory concentrations of moxifloxacin against adhesion, biofilm formation, and cell-surface hydrophobicity of two strains of Stenotrophomonas maltophilia isolated from CF patients. Adhesion and biofilm formation assays were carried out on polystyrene and quantified by colony counts. CSH was determined by adhesion to n-hexadecane test. Moxifloxacin at 0.03x and 0.06xMIC caused a significant decrease of adhesion...
Source: Journal of Medical Microbiology - September 16, 2009 Category: Microbiology Authors: Pompilio A, Catavitello C, Picciani C, Confalone P, Piccolomini R, Savini V, Fiscarelli E, D'Antonio D, Di Bonaventura G Tags: J Med Microbiol Source Type: journals

Moxifloxacin-Containing Triple Therapy as Second-Line Treatment for Helicobacter pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication RateEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: The 7-day moxifloxacin-containing triple therapy produced an unacceptably low eradication rate. Increasing the duration of therapy was expected to increase the eradication rate, but the expected increased did not materialize, most likely because of coincident marked increase in the prevalence of resistance to moxifloxacin. Tailored treatment based on antibiotic susceptibility testing might be more effective in the achievement of high eradication rate when rapid antibiotic resistance such as moxifloxacin is occurring. (Source: Helicobacter)
Source: Helicobacter - September 10, 2009 Category: Gastroenterology Authors: Hyuk Yoon, Nayoung Kim, Byoung Hwan Lee, Tae Jun Hwang, Dong Ho Lee, Young Soo Park, Ryoung Hee Nam, Hyun Chae Jung, In Sung Song Tags: ORIGINAL ARTICLES Source Type: journals

Antimicrobial susceptibilities of Mycoplasma genitalium by broth dilution and quantitative PCR.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Only limited information regarding the antimicrobial susceptibilities of Mycoplasma genitalium is available because of difficulties in isolating M. genitalium strains from clinical specimens. Antimicrobial susceptibilities of 15 clinical isolates, 7 ATCC strains and an early-passage of the M30 strain were examined by the broth-dilution method. Azithromycin, clarithromycin, sitafloxacin and moxifloxacin were the most active drugs to M. genitalium and their MIC90 values were 0.002, 0,008, 0.125 and 0.125 mg/liter, respectively. PMID: 19738019 [PubMed - as supplied by publisher] (Source: Antimicrobial Agents and Chemotherapy)
Source: Antimicrobial Agents and Chemotherapy - September 7, 2009 Category: Microbiology Authors: Hamasuna R, Jensen JS, Osada Y Tags: Antimicrob Agents Chemother Source Type: journals

In vitro Activity of Nemonoxacin, a Novel Non-fluorinated Quinolone, against 2,440 Clinical Isolates.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The in vitro activity of nemonoxacin, a novel non-fluorinated quinolone, was tested against 2,440 clinical isolates. Nemonoxacin was at least 4 fold more active than levofloxacin and moxifloxacin against most Gram-positive cocci tested [MIC90/range (microg/ml): community-associated methicillin-resistant Staphylococcus aureus, 0.5/0.015-2; Staphylococcus epidermidis, 0.5/0.015-4 (methicillin-susceptible), 2/0.12-2 (methicillin-resistant); Streptococcus pneumoniae, 0.015/</=0.008-0.25; Enterococcus faecalis, 1/0.03-128]. Activity against Gram-negative bacilli was similar to levofloxacin and moxifloxacin [MIC90/range (...
Source: Antimicrobial Agents and Chemotherapy - September 7, 2009 Category: Microbiology Authors: Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG Tags: Antimicrob Agents Chemother Source Type: journals

Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Analog for Treatment of Type 2 Diabetes.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective of this study was to establish effects of liraglutide on the QTc interval. In this randomized, placebo-controlled, double-blind crossover study, 51 healthy participants were administered placebo, 0.6, 1.2, and 1.8 mg liraglutide once daily for 7 days each. Electrocardiograms were recorded periodically over 24 hours at the end of placebo and highest dosing periods. Four different models for QT correction were used: QTci, as the primary endpoint, and QTciL, QTcF, and QTcB as secondary endpoints. The upper bound of the 1-sided 95% confidence interval for time-matched, baseline-corrected, placebo-subtracted QTc i...
Source: The Journal of Clinical Pharmacology - September 7, 2009 Category: Drugs & Pharmacology Authors: Chatterjee DJ, Khutoryansky N, Zdravkovic M, Sprenger CR, Litwin JS Tags: J Clin Pharmacol Source Type: journals

Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid and Plasma in Patients with Tuberculous MeningitisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Clinical Infectious Diseases, Volume 0, Issue 0, Page 000, Latest Articles. Moxifloxacin cerebrospinal fluid (CSF) penetration was evaluated by obtaining full plasma and CSF time concentration curves for 4 patients with tuberculous meningitis. The geometric mean ratio of the areas under the curve for CSF to plasma were 0.82 (range, 0.70–0.94) at 400 mg once per day and 0.71 (0.58–0.84) at 800 mg once per day. (Source: Clinical Infectious Diseases Latest Issue)
Source: Clinical Infectious Diseases Latest Issue - August 27, 2009 Category: Infectious Diseases Tags: article BRIEF REPORT Source Type: journals

Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for IKsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion and implications: Doxorubicin acutely prolonged the QT interval in guinea-pig heart by selective IKs blockade. This effect was prevented by dexrazoxane. This result is important because it illustrates the danger of neglecting IKs in favour of hERG screening alone, for early preclinical testing for possible induction of torsade de pointes. (Source: British Journal of Pharmacology)
Source: British Journal of Pharmacology - August 23, 2009 Category: Drugs & Pharmacology Authors: J Ducroq, H Moha ou Maati, S Guilbot, S Dilly, E Laemmel, C Pons-Himbert, JF Faivre, P Bois, O Stücker, M Le Grand Source Type: journals

Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired PneumoniaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: In-hospital treatment of CAP with IV moxifloxacin 400 mg or IV levofloxacin 750 mg was associated with similar hospital LOS and costs in propensity-matched cohorts. (Source: Value in Health)
Source: Value in Health - August 19, 2009 Category: Global & Universal Authors: Howard Friedman, Xue Song, Simone Crespi, Prakash Navaratnam Source Type: journals

AVELOX (Moxifloxacin Hydrochloride) Injection, Solution AVELOX (Moxifloxacin Hydrochloride) Tablet, Film Coated [Schering Plough Corporation]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Aug 19, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 19, 2009 Category: Drugs & Pharmacology Source Type: organizations

Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infectionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Management of community-origin complicated intra-abdominal infections (cIAIs) requires surgical intervention and antimicrobial therapy. This multinational, randomised, double-blind clinical trial carried out in Asia compared the efficacy and safety of moxifloxacin monotherapy and ceftriaxone/metronidazole combination therapy in adults with confirmed or suspected cIAI. Patients received surgical intervention and either intravenous (i.v.) moxifloxacin 400mg once daily or i.v. ceftriaxone 2g once daily plus i.v. metronidazole 500mg twice daily. A total of 364 patients were randomised [intent-to-treat (ITT), moxiflox...
Source: International Journal of Antimicrobial Agents - August 18, 2009 Category: Drugs & Pharmacology Authors: Joseph Solomkin, Yu-Pei Zhao, En-Ling Ma, Min-Jun Chen, Barbara Hampel, Members of the DRAGON Study Team Tags: Full length articles Source Type: journals

Kill rates of preserved and preservative-free topical 8-methoxy fluoroquinolones against various strains of StaphylococcusEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Purpose: To assess the kill rates of preserved and preservative-free 8-methoxy fluoroquinolones and benzalkonium chloride (BAC) against isolates of Staphylococcus aureus and coagulase-negative Staphylococcus (CNS) species.Setting: Bascom Palmer Eye Institute, Miami, Florida, USA.Methods: Ocular and standard isolates of S aureus and CNS were inoculated with saline, 0.005% BAC, gatifloxacin 0.3% containing 0.005% BAC (Zymar), or BAC-free moxifloxacin 0.5% (Vigamox) at 37°C. Bacterial viability was assessed after 15 minutes, 30 minutes, and 60 minutes.Results: Thirteen isolates of S aureus and 5 isolates of CNS were used. Th...
Source: Journal of Cataract and Refractive Surgery - August 18, 2009 Category: Opthalmology Authors: Joon Young Hyon, Ilker Eser, Terrence P. O'Brien Tags: Laboratory Science Source Type: journals

Aqueous humor penetration of fourth-generation fluoroquinolone ophthalmic solutions given by multiple administration in a rabbit modelEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract We investigated the aqueous humor concentration of topically applied gatifloxacin (GFLX) 0.3% and moxifloxacin (MFLX) 0.5% in a rabbit model of surgical and nonsurgical eyes. Topical administration in eyes was performed eight times, at 15-min intervals. Surgical eyes had undergone cataract surgery with the implantation of an intraocular lens (IOL). Aqueous humor was sampled at 5, 30, and 120 min after drug administration. Drug concentrations were determined by high-performance liquid chromatography (HPLC). The GFLX concentrations in surgical eyes at 5, 30, and 120 min post-administration were 12.1, ...
Source: Journal of Infection and Chemotherapy - August 17, 2009 Category: Infectious Diseases Tags: Journal of Infection and Chemotherapy Source Type: journals

Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study evaluated cross-resistance among ofloxacin, moxifloxacin and gatifloxacin and investigated the presence of mutations in gyrA and gyrB. Fluoroquinolone susceptibility was determined in 41 M. tuberculosis strains by the proportion method on 7H11 and minimal inhibitory concentrations were determined by the resazurin microtiter assay. Forty strains shared the same resistance results for the three fluoroquinolones. However, one strain with mutation at Asn-533-->Thr in gyrB was susceptible to ofloxacin but resistant to moxifloxacin and gatifloxacin. PMID: 19687244 [PubMed - as supplied by publisher] (Source: An...
Source: Antimicrobial Agents and Chemotherapy - August 16, 2009 Category: Microbiology Authors: VON Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, Palomino JC, Almeida DA Silva P Tags: Antimicrob Agents Chemother Source Type: journals

Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bacillus anthracis is complex because of its spore form. The spore is invulnerable to antibiotic action. It also has an impact on the resistance emergence. We employed the hollow fiber infection model to study the impact of different doses and schedules of moxifloxacin on the total organism population, the spore population and the subpopulations of vegetative- and spore-phase organisms that were resistant to moxifloxacin. We then generated a mathematical model of the impact of moxifloxacin on vegetative- and spore-phase organisms when administered by continuous-infusion or daily-administration. The ratio of rate consta...
Source: Antimicrobial Agents and Chemotherapy - August 16, 2009 Category: Microbiology Authors: Drusano GL, Okusanya OO, Okusanya AO, van Scoy B, Brown DL, Fregeau C, Kulawy R, Kinzig M, Sörgel F, Heine HS, Louie A Tags: Antimicrob Agents Chemother Source Type: journals

Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The prophylactic potential of moxifloxacin and gatifloxacin was assessed in comparison with doxycycline, an established therapeutic antibiotic, to limit or control infection by Brucella melitensis in an experimental mouse model, determined by reduced bacterial burden in the spleen. Although moxifloxacin was found to have a small protective effect when administered 6h following infection, neither moxifloxacin nor gatifloxacin showed significant efficacy in vivo. In comparison, doxycycline provided significant protection when prophylaxis was started at 6h, 7 days or 14 days following infection. Overall, these resul...
Source: International Journal of Antimicrobial Agents - August 16, 2009 Category: Drugs & Pharmacology Authors: Helen S. Atkins, Stephen Spencer, Simon D. Brew, Thomas R. Laws, Rachel E. Thirlwall, Alastair P. MacMillan, Timothy J.G. Brooks, Andrew J.H. Simpson Tags: Short communications Source Type: journals

Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolatesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: We evaluated the pharmacokinetic/pharmacodynamic parameters of 8 oral quinolones (ciprofloxacin, garenoxacin [GRNX], gatifloxacin, levofloxacin, moxifloxacin, prulifloxacin, sitafloxacin, and sparfloxacin) on 11 fluoroquinolone-resistant Streptococcus pneumoniae strains, screened from 780 strains isolated from various clinical sources in Japan. GRNX showed the highest area under the blood concentration time curve/MIC ratios, which exceeded the target values for bacterial eradication against all fluoroquinolone-resistant S. pneumoniae strains. (Source: Diagnostic Microbiology and Infectious Disease)
Source: Diagnostic Microbiology and Infectious Disease - August 13, 2009 Category: Microbiology Authors: Shin-ichi Yokota, Yasuo Ohkoshi, Nobuhiro Fujii Tags: Notes Source Type: journals

Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection modelEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Our results suggest that suboptimal dosing may facilitate resistance amplification in a high inoculum of E. coli. The clinical dose of moxifloxacin (400 mg/day) was adequate to suppress resistance development in three wild-type strains. Clinical relevance of these findings warrants further in vivo investigation. (Source: Journal of Antimicrobial Chemotherapy)
Source: Journal of Antimicrobial Chemotherapy - August 10, 2009 Category: Microbiology Authors: Singh, R., Ledesma, K. R., Chang, K.-T., Hou, J.-G., Prince, R. A., Tam, V. H. Tags: Original research Source Type: journals